These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 26799743)

  • 1. Improved Muscle Function in Duchenne Muscular Dystrophy through L-Arginine and Metformin: An Investigator-Initiated, Open-Label, Single-Center, Proof-Of-Concept-Study.
    Hafner P; Bonati U; Erne B; Schmid M; Rubino D; Pohlman U; Peters T; Rutz E; Frank S; Neuhaus C; Deuster S; Gloor M; Bieri O; Fischmann A; Sinnreich M; Gueven N; Fischer D
    PLoS One; 2016; 11(1):e0147634. PubMed ID: 26799743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial.
    Hafner P; Bonati U; Rubino D; Gocheva V; Zumbrunn T; Gueven N; Fischer D
    Trials; 2016 Aug; 17(1):389. PubMed ID: 27488051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of single and combined metformin and L-citrulline supplementation on L-arginine-related pathways in Becker muscular dystrophy patients: possible biochemical and clinical implications.
    Hanff E; Hafner P; Bollenbach A; Bonati U; Kayacelebi AA; Fischer D; Tsikas D
    Amino Acids; 2018 Oct; 50(10):1391-1406. PubMed ID: 30003335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a long-term treatment with metformin in dystrophic mdx mice: A reconsideration of its potential clinical interest in Duchenne muscular dystrophy.
    Mantuano P; Sanarica F; Conte E; Morgese MG; Capogrosso RF; Cozzoli A; Fonzino A; Quaranta A; Rolland JF; De Bellis M; Camerino GM; Trabace L; De Luca A
    Biochem Pharmacol; 2018 Aug; 154():89-103. PubMed ID: 29684379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Combination l-Citrulline and Metformin Treatment on Motor Function in Patients With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
    Hafner P; Bonati U; Klein A; Rubino D; Gocheva V; Schmidt S; Schroeder J; Bernert G; Laugel V; Steinlin M; Capone A; Gloor M; Bieri O; Hemkens LG; Speich B; Zumbrunn T; Gueven N; Fischer D
    JAMA Netw Open; 2019 Oct; 2(10):e1914171. PubMed ID: 31664444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic strategies to address neuronal nitric oxide synthase deficiency and the loss of nitric oxide bioavailability in Duchenne Muscular Dystrophy.
    Timpani CA; Hayes A; Rybalka E
    Orphanet J Rare Dis; 2017 May; 12(1):100. PubMed ID: 28545481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids.
    Hörster I; Weigt-Usinger K; Carmann C; Chobanyan-Jürgens K; Köhler C; Schara U; Kayacelebi AA; Beckmann B; Tsikas D; Lücke T
    Amino Acids; 2015 Sep; 47(9):1853-63. PubMed ID: 26066683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial.
    Nagy S; Hafner P; Schmidt S; Rubino-Nacht D; Schädelin S; Bieri O; Fischer D
    Trials; 2019 Nov; 20(1):637. PubMed ID: 31752977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arginine butyrate: a therapeutic candidate for Duchenne muscular dystrophy.
    Vianello S; Yu H; Voisin V; Haddad H; He X; Foutz AS; Sebrié C; Gillet B; Roulot M; Fougerousse F; Perronnet C; Vaillend C; Matecki S; Escolar D; Bossi L; Israël M; de la Porte S
    FASEB J; 2013 Jun; 27(6):2256-69. PubMed ID: 23430975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nitric oxide and l-arginine cause an accumulation of utrophin at the sarcolemma: a possible compensation for dystrophin loss in Duchenne muscular dystrophy.
    Chaubourt E; Fossier P; Baux G; Leprince C; Israël M; De La Porte S
    Neurobiol Dis; 1999 Dec; 6(6):499-507. PubMed ID: 10600405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The serum nitric oxide levels in patients with Duchenne muscular dystrophy.
    Gücüyener K; Ergenekon E; Erbas D; Pinarli G; Serdaroğlu A
    Brain Dev; 2000 May; 22(3):181-3. PubMed ID: 10814901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression and variation of fatty infiltration of the thigh muscles in Duchenne muscular dystrophy, a muscle magnetic resonance imaging study.
    Li W; Zheng Y; Zhang W; Wang Z; Xiao J; Yuan Y
    Neuromuscul Disord; 2015 May; 25(5):375-80. PubMed ID: 25701397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of sildenafil on skeletal and cardiac muscle in Becker muscular dystrophy.
    Witting N; Kruuse C; Nyhuus B; Prahm KP; Citirak G; Lundgaard SJ; von Huth S; Vejlstrup N; Lindberg U; Krag TO; Vissing J
    Ann Neurol; 2014 Oct; 76(4):550-7. PubMed ID: 25042931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NO vascular control in Duchenne muscular dystrophy.
    Crosbie RH
    Nat Med; 2001 Jan; 7(1):27-9. PubMed ID: 11135610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative MRI and strength measurements in the assessment of muscle quality in Duchenne muscular dystrophy.
    Wokke BH; van den Bergen JC; Versluis MJ; Niks EH; Milles J; Webb AG; van Zwet EW; Aartsma-Rus A; Verschuuren JJ; Kan HE
    Neuromuscul Disord; 2014 May; 24(5):409-16. PubMed ID: 24613733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy.
    Escolar DM; Buyse G; Henricson E; Leshner R; Florence J; Mayhew J; Tesi-Rocha C; Gorni K; Pasquali L; Patel KM; McCarter R; Huang J; Mayhew T; Bertorini T; Carlo J; Connolly AM; Clemens PR; Goemans N; Iannaccone ST; Igarashi M; Nevo Y; Pestronk A; Subramony SH; Vedanarayanan VV; Wessel H;
    Ann Neurol; 2005 Jul; 58(1):151-5. PubMed ID: 15984021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-point technique of fat quantification of muscle tissue as a marker of disease progression in Duchenne muscular dystrophy: preliminary study.
    Wren TA; Bluml S; Tseng-Ong L; Gilsanz V
    AJR Am J Roentgenol; 2008 Jan; 190(1):W8-12. PubMed ID: 18094282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy.
    Villalta SA; Nguyen HX; Deng B; Gotoh T; Tidball JG
    Hum Mol Genet; 2009 Feb; 18(3):482-96. PubMed ID: 18996917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Airway nitric oxide in Duchenne muscular dystrophy.
    Straub V; Ratjen F; Amthor H; Voit T; Grasemann H
    J Pediatr; 2002 Jul; 141(1):132-4. PubMed ID: 12091865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.